Authors
Plavinski S. L.
1
Shabalkin P.I.
2
1 - North-West State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia
2 - Federal Scientific and Clinical Centre of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, Moscow, Russia
Abstract
Preterm births are serious life-threatening complication of pregnancy which bears a high risk of death and other complications both in mother and child. Today many efficient options exist for tocolysis, that is prolongation of pregnancy necessary to maturation of fetus’s lung. Selection of optimal therapy usually done based on effectiveness and safety profile, but in third-payer setting economical aspect of treatment if also important. The cost-minimization analysis and budget impact analysis show that in Russian setting use of atosiban will result in significant savings.
Key words
atosiban, preterm birth, cost minimization analysis, budget impact analysis
References
1. Costeloe, K., Hennessy E., Gibson A.T. et al. «The EPICure study: outcomes to discharge from hospital for infants born at the threshold of viability.» Pediatrics Vol. 106, no. 4. (2000): 659-671.
2. Wood, N.S, Marlow N., Costeloe K. et al. «Neurologic and developmental disability after extremely preterm birth. EPICure Study Group.» N. Engl. J. Med. Vol. 343, no. 6 (2000): 378-384.
3. Roberts, D. «Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth.» Cochrane Database Syst Rev. 3 (2006): CD004454.
4. Di Renzo, G. C. «Guidelines for the management of spontaneous preterm labor.» J Perinat Med. Vol. 34, no. 5 (2006): 359-366.
5. Haas, D.M, Caldwell D.M, Kirkpatrick P. et al. «Tocolytic therapy for preterm delivery: systematic review and network meta-analysis.» BMJ Vol. 345 (2012): e6226.
6. Papatsonis, D., Flenady V., Cole S., Liley H. «Oxytocin receptor antagonists for inhibiting preterm labour.» Cochrane Database Syst Rev. 3 (2005): CD004452.
7. Romero, R., Sibai B.M, Sanchez-Ramos L. et al. «An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue.» Am. J. Obstet. Gynecol. Vol. 182, no. 5 (2000): 1173-1183.
8. Moutquin, J. M, Sherman D., Cohen H. et al. «Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study.» Am. J. Obstet. Gynecol. Vol. 182, no. 5 (2000): 1191-1199.
9 Wex J, Abou-Setta A. M, Clerici G., Di Renzo G.C «Atosiban versus betamimetics in the treatment of preterm labour in Italy: clinical and economic importance of side-effects.» Eur. J. Obstet. Gynecol. Reprod. Biol. Vol. 157, no. 2 (2011): 128–135.
10. Wex, J, «Atosiban versus betamimetics in the treatment of preterm labour in Germany: an economic evaluation.» BMC Pregnancy Childbirth. 9 (2009): 23.
11. Jakovljevic, M, «Cost-effectiveness of ritodrine and fenoterol for treatment of preterm labor in a low-middle-income country: a case study.» Value Health. Vol. 11, no. 2. (2008): 149-153.
12. Roos, C, Spaanderman M.E, Schuit E. et al. «Effect of maintenance tocolysis with nifedipine in threatened preterm labor on perinatal outcomes: a randomized controlled trial.» JAMA. Vol. 309, no. 1. (2013): 41-47.
13. Salim, R, Garmi G, Nachum Z. et al. «Nifedipine compared with atosiban for treating preterm labor: a randomized controlled trial.» Obstet Gynecol. Vol. 120, no. 6. (2012): 1323-1331.
14. Neilson, J. P «Betamimetics for inhibiting preterm labour.» Cochrane Database Syst Rev. 2 (2014): CD004352.
15. Mad, P, Geiger-Gritsch S, Mittermayr T, Wild C. «Medikamentoese Wehenhemmung bei drohender Fruehgeburt.» Wien: Ludwig Boltzmann Institut fuer Health Technology Assessment, 2009. Print.
16. Sukhih, G.T, Khodjaeva Z.S, Filippov O.S. et al. «Miscarriage. Clinical Recommendations.» Moscow: Research Center for Obstetrics, Gynecology and Perinatology, 2014. Print.
